Home | Welcome to Contract Pharma   
Last Updated Monday, March 30 2015


GVK BIO To Acquire Aragen Bioscience

By Kristin Brooks

Published January 29, 2014
Related Searches: CRO preclinical cro Preclinical
GVK BIO has entered an agreement to acquire Aragen Bioscience, Inc., a privately held U.S. based, preclinical CRO specializing in biologics services. GVK BIO is small molecule service provider in Asia. The acquisition expands GVK BIO’s service offering to a broader client base and provides expertise in biologics services, as well as a significant U.S. presence. Financial terms were not disclosed.
"As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform,” said Mr. D. S. Brar, chairman, GVK BIO.
"Aragen’s scientific excellence and expertise in large-molecule R&D services combined with GVK BIO’s scale, resources, and global reach will create significant synergies for both companies,” said Rick Srigley, president and chief executive officer, Aragen Bioscience.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On